Thus, our aim in the present study is to re-analyse the MS risk conferred by HLA class II variants and specifically determined by both DRB1* and DQB1* alleles (DRB1*- DQB1* haplotype) in a more consistent sample of Sardinian MS families. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.